Bridging stakeholders with biotechnology Accelerated path to human trials Growing knowledge base Ensuring dependability BioViva is a platform to expedite the development of drugs and treatments that affect human healthspan. To achieve this goal BioViva has developed
Bridging stakeholders with biotechnology Accelerated path to human trials Growing knowledge base Ensuring dependability BioViva is a platform to expedite the development of drugs and treatments that affect human healthspan. To achieve this goa
BBC World reporter Gabriela Torres met Liz to discuss BioViva's project to make therapies shown to be safe in animals available to humans at an affordable price in the near future.
The Economist held a conference on October 27, 2017, about the economic impact of extreme longevity and the transition to an older, productive population. CEO Liz Parrish was invited.
The company describes clinics and products for diagnosing age-related dysfunction, predicting ill health, preventing sickness with gene and cell therapies, and supporting health with nutrition through personalized, precision, preventive, and participatory medicine.
BioViva secures a patent for a gene-therapy method combining **hTERT** and **Follistatin-344** to address age-related decline. The approach targets **telomere length, muscle mass, and blood-glucose regulation** in related diseases. The patent covers a novel dual-gene strategy for potential anti-aging interventions.
BioViva obtains a U.S. patent for a gene therapy combining **hTERT** and **Follistatin-344** to address age-related disorders. The therapy targets **telomere maintenance, muscle biology, and metabolic function** as part of a dual-gene approach. The patent, **U.S. Patent No. 12,653,907**, covers this innovative strategy for potential clinical applications.
BioViva Science introduces a **CMV vector-based platform** to improve gene-therapy delivery for aging-related diseases. The company targets complex conditions through its novel approach, aiming to enhance treatment efficacy. This technology represents a potential advancement in gene-editing precision for degenerative disorders.
BioViva Science advances gene therapy delivery methods and healthy longevity research based on 2022 findings. The company now prepares to launch a Series A funding round in 2023 to support further development. Breakthroughs focus on potential applications in extending human healthspan through genetic interventions.
BioViva’s gene therapies, delivered via a CMV vector, extend healthy lifespans by over 40% in test subjects. The treatments also improve multiple health markers, including metabolic and cellular function. These patent-pending therapies target aging-related decline through genetic modification.
Bioviva’s CEO reports the company’s gene therapy for aging reduced her biological age by 20 years. The treatment marks what the firm calls the first successful gene therapy directly targeting human aging. No clinical trial data or independent verification is provided in the claim.